Global University Venturing

The Oxford-linked oncology drug developer has raised the money from new and existing backers, and will use the cash to boost its product pipeline.

Johnson & Johnson Innovation – JJDC has co-led the computational pathology technology provider's series C round to take its total funding to $195m.

Luba Greenwood has been brought on to run Binney Street Capital on behalf of cancer research and care provider Dana-Farber Cancer Institute.

Atalanta Therapeutics has launched out of UMass with $110m in combined series A and partnership funding to develop therapies for neurodegenerative diseases.

Three years after launching to commercialise stem cell research from Harvard University, Sana has filed for an initial public offering.

University of Michigan and Virginia-founded Everactive has reached its series C target after three tranches.

Former senior sales director Darren Winter has joined Frontier IP to support its portfolio companies with fundraising.

USF's senior vice-president for research and innovation Paul Sanberg will return to being a distinguished professor in neurosurgery and brain repair.

The eye disease device developer has raised series B funding to advance research originating from University of Colorado's s Sue Anschutz-Rodgers Eye Center.

Four of the incubator’s portfolio companies will pitch to investors at the GCV Digital Forum 3.0 following the success of similar competitions at our previous events.

Weill Cornell Medicine‘s monogenic diseases therapy developer Lexeo Therapeutics has made its public debut with $85m in series A financing.